Baidu algorithm-based mRNA vaccine neutralizing antibody titer levels exceed benchmark sequence by up to 20x

Oct. 19, 2021

By Doris Yu

Baidu Inc.’s preclinical studies showed the mRNA vaccine sequences for COVID-19 designed using its Lineardesign algorithm outperformed the benchmark sequences designed by traditional algorithms in terms of stability, protein expression and immunogenicity. The firm teamed up with Stemirna Therapeutics Co. Ltd., which specializes in the R&D of mRNA vaccines and drugs, to test seven mRNA COVID-19 vaccine sequences designed using Lineardesign.

https://www.bioworld.com/articles/51...e-by-up-to-20x